Solskin On 08/08/2024, Royalty Pharma plc (NASDAQ:RPRX) presented its Q2 earnings. Following a solid Q1, the company raised its 2024 outlook, with Portfolio Receipts expected to achieve $2.7/2.75 billion results. We positively view this announcement; however, today, we decided to focus on an ongoing downside. Downside Protection In our initiation of coverage, we reported how the Vertex franchise is one of the most significant portfolio receipt contributors. In detail, we explained: The cystic fibrosis franc ...

Solskin Introduction Since I last covered Royalty Pharma (NASDAQ:RPRX) back in January last year, the company has been an underperformer returning a -10% return while the market has gone in the opposite direction proportionally. At the time, my investment thesis was based upon three main points: 1. Royalty Pharma has a track record of compounding value. 2. The company has a durable competitive advantage in the biopharma royalty space. 3. The future outlook for the company's growth is looking better driven b ...

Royalty Pharma plc (NASDAQ:RPRX) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants George Grofik – Senior Vice President, Head of Investor Relations and Communications Pablo Legorreta – Founder and Chief Executive Officer Marshall Urist – Executive Vice President, Head-Research and Investments Chris Hite – Executive Vice President, Vice Chairman Terry Coyne – Executive Vice President, Chief Financial Officer Conference Call Participants Chris Shibutani – Goldman Sachs Hardik Pa ...

ROYALTY PHARMA ROYALTY PHARMA Royalty Pharma plc Q2 2024 Financial Results August 8, 2024 2 Forward Looking Statements & Non-GAAP Measures This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the dat ...

Royalty Pharma (RPRX) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.85 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 1.05%. A quarter ago, it was expected that this company would post earnings of $0.96 per share when it actually produced earnings of $0.98, delivering a surprise of 2.08%. Over the last four quarters, the company h ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________ to __________ Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 ...

Exhibit 99.1 LTY PHARMA ROYALTY PHARMA REPORTS SECOND QUARTER 2024 RESULTS • Portfolio Receipts growth of 12% to $608 million; Royalty Receipts growth of 11% • Net cash provided by operating activities of $658 million • Raising full year 2024 guidance: Portfolio Receipts expected to be $2,700 to $2,775 million NEW YORK, NY, August 8, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts. "We delivere ...

Core Insights - Royalty Pharma plc has appointed Molly Sawaya as Executive Vice President, Head of Human Capital, effective July 24, 2024 [1][4] Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry [8] - The company collaborates with various entities, including academic institutions, research hospitals, non-profits, and biotechnology companies, to fund innovation [8] - Royalty Pharma's portfolio includes royalties on over 35 commercial products, such as Vertex's Trikafta and GSK's Trelegy, as well as 17 development-stage product candidates [8] Leadership Appointment - Molly Sawaya brings nearly 15 years of HR experience from large global organizations, focusing on creating environments for employee growth and engagement [4][7] - Prior to joining Royalty Pharma, Sawaya was a Managing Director at Hudson Bay Capital, where she led the HR agenda [7] - The CEO of Royalty Pharma, Pablo Legorreta, expressed confidence in Sawaya's ability to enhance the company's culture and support its growth [4]

Company Overview - Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry, founded in 1996 [2] - The company collaborates with innovators from academic institutions, research hospitals, non-profits, and biopharmaceutical companies, funding innovation directly and indirectly [2] - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 17 development-stage product candidates, such as Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, and others [2] Leadership Appointment - Molly Sawaya has been appointed as Executive Vice President, Head of Human Capital at Royalty Pharma [4] - Molly brings nearly 15 years of HR experience from large global organizations, including Hudson Bay Capital, QBE Insurance Group, Perpetual Limited, and National Australia Bank [1][8] - Her role will focus on fostering a culture of growth and supporting the scaling of the business [8] Business Model - Royalty Pharma funds innovation directly by partnering with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties [2] - Indirectly, the company acquires existing royalties from original innovators, building a portfolio tied to the top-line sales of leading therapies [2]

Conference Call Information About Royalty Pharma Royalty Pharma Investor Relations and Communications NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Please visit the "Investors" page of the company's website at https://www.royaltyphar ...